Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally...
Medical experts, Dr. Joan Culpepper-Morgan and Dr. Susanne G. Warner, touch upon treatment advancements for patients presenting with hepatocelluar carcinoma (HCC). In this article, both doctors cover a range of therapies that can be tailored and personalized to the...
In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%. Up to 80% of people with this type of HCC experience disease recurrence, at which point they are...
In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the...
Dr. Sapna Patel from MD Anderson presented early data from the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial at SITC’s Tumor Microenvironment: A Holistic Approach Workshop. Early findings suggest Pressure-Enabled Drug Delivery™ enabled SD-101...
A Cure in Sight, in collaboration with the Ocular Melanoma Foundation, hosted an educational webinar on the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial for uveal melanoma with liver metastases. This webinar featured insights from Drs....
Pivotal Trials Look to Shake Up HCC Treatment Hepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.Hepatocellular cancer (HCC), the most common primary liver malignancy, is the fourth-leading...
Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity. Primary liver cancer is a leading cause of cancer-related illness and death worldwide. It is the sixth most-common cancer and the third most-common cause of...
Health related quality of life (HRQOL) for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with...
Hepatocellular carcinoma is a common cancer worldwide and a leading cause of cancer-related death. Although early-stage disease may be curable by resection, liver transplantation, or ablation, most patients present with unresectable disease and have a poor prognosis....